-

DSG and Bestat Partner in Building COVID-19 Clinical Trials in Singapore

MALVERN, Pa.--(BUSINESS WIRE)--DSG, Inc., a global leader of eClinical software solutions and services for the life sciences industry along with their CRO partner, Bestat Pharmaservices Corp. (Bestat) are building studies to support COVID-19 treatments and vaccines in Asia. This includes a study now progressing to Phase III that evaluates a novel monoclonal antibody as a treatment to neutralize SARS-CoV-2 by binding to specific proteins found on the surface of the virus.

With the medical community facing extraordinary challenges, as it desperately searches for a vaccine to slow the progression and accelerate recovery of SARS-CoV-2, it is critical to have the ability to build effective clinical trial solutions at a rapid pace and also be adaptive to the ever changing landscape and challenges brought on by the pandemic. DSG, with its proven and intuitive eCaseLink platform provides the right tools for Bestat to achieve these goals.

DSG’s platform enabled Bestat to rapidly build solutions for data collection, management and analysis, helping the clinical trials progress all the way from Phase I to Phase III in a very efficient and accelerated manner by ensuring clean data with real time data export and tools for analysis. Bestat primarily leveraged the eCaseLink Designer module to build the studies in-house in just a few days, while maintaining the integrity for these demanding trials and timelines. The eCaseLink Designer and EDC module helped create and manage the development of electronic clinical trial research questionnaires for the sponsors to effectively collect data from participating patients. Due to the success of these trials, Bestat has contracted with DSG to utilize the Interactive Response Technology (IRT) to manage Randomization and Drug Supply Management (RTSM) for the upcoming Phase III studies.

“We believe that with strong partners, DSG can provide the most effective solutions in the race to find a cure for this pandemic,” said Tony Varano, CEO at DSG. “We applaud Bestat and their team for efficiently using our eCaseLink platform and with their expertise, conducting effective trials and moving them closer to the finish line.”

About DSG

DSG, Inc. is a leading global eClinical provider with a unified suite of innovative technology solutions for the global clinical research community. DSG's eClinical software platform provides competitive advantage that is cost-effective and quickest to build. DSG’s award-winning eCaseLink solutions are used in thousands of clinical trials around the globe.

About Bestat

Bestat is a contract research organization (CRO) dedicated to offering solutions to our customers with the highest quality and professional attitude through time-efficient clinical trial management and data processing. The value professionalism Bestat delivers is expertise leveraged over a broad range of services, and a passionate and talented team of experts to help you make the best decision in conducting clinical trial or research. Having directly served a number of internationally recognized pharmaceutical, biomedical companies and institutes, we have confidences to be trusted as your best partner in clinical trial areas. (https://www.bestat.com.tw/)

Contacts

Ricky Lee Brohmer
DSG, Inc.
+1 262-219-2168
rbrohmer@dsg-us.com

DSG, Inc.

Details
Headquarters: Malvern, PA
CEO: Anthony Varano
Employees: 170
Organization: PRI

Release Versions

Contacts

Ricky Lee Brohmer
DSG, Inc.
+1 262-219-2168
rbrohmer@dsg-us.com

More News From DSG, Inc.

DSG and 1nHealth Partner to Enhance Patient Outreach and Enrollment Capabilities

MALVERN, Pa.--(BUSINESS WIRE)--DSG, Inc., a global leader of eClinical software solutions and services, along with 1nHealth, a global digital patient recruitment provider, are creating a seamless participant experience from the initial study launch to completion of study participation. This includes integrating pre-screened leads from 1nHealth’s secure platform into DSG’s eCaseLink Enrollment Tracker to allow participants to seamlessly enroll and capture consent while eliminating delays and roa...

DSG Supports PhaseBio Pharmaceuticals with Unified Clinical Trial Software Platform for COVID-19 Trial

MALVERN, Pa.--(BUSINESS WIRE)--DSG, Inc., a global leader of eClinical software solutions and services for the life sciences industry has successfully launched a COVID-19 study with PhaseBio Pharmaceuticals for its potentially pivotal clinical trial evaluating PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome (ARDS). Understanding the urgent nature and the challenges faced by physicians looking...

DSG Developing Adaptive Solutions for Multiple Phase 3 Clinical Trials for COVID-19 Treatment

MALVERN, Pa.--(BUSINESS WIRE)--DSG, Inc. is supporting two Phase 3 studies sponsored by Romark, L.C. to evaluate an investigational new drug for prevention of COVID-19 in elderly residents of long-term care facilities and healthcare workers. Given the urgent nature of the COVID-19 pandemic, getting a trial up and running fast is crucial but even more critical is to build a trial that is adaptive with all the uncertainties and challenges of the current situation. DSG, with 28 years of experience...
Back to Newsroom